Dicerna Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€165.47M - Cost of goods sold
€0.00 - Gross profit
€165.47M - SG&A expenses
€74.40M - R&D expenses
€195.12M - EBITDA
-€101.70M - D&A
€3.90M - EBIT
-€104.05M - Interest expenses
€10.30K - EBT
-€105.60M - Tax expenses
€1.16M - Net income
-€106.77M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€42.81M - Changes in working capital
€123.52M - Operating cash flow
€18.06M - Capex
€10.72M - Other investing cash flow
€0.00 - Net investing cash flow
-€78.78M - Total cash dividends paid
€0.00 - Issuance of common stock
-€33.63M - Debt repayment
€0.00 - Other financing cash flow
€27.03M - Net financing cash flow
€27.03M - Foreign exchange effects
€0.00 - Net change in cash
-€33.69M - Cash at end of period
€147.04M - Free cash flow
€28.78M
Balance sheet
- Cash and cash equivalents
€142.22M - Cash and short-term investments
€485.21M - Total receivables
€5.34M - Inventory
€0.00 - Other current assets
€14.82M - Total current assets
€505.37M - Property, plant & equipment
€81.11M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€69.57M - Other non-current assets
€6.39M - Total non-current assets
€157.06M - Total assets
€662.43M - Accounts payable
€7.14M - Short-term debt
€4.20M - Other current liabilities
€29.28M - Total current liabilities
€205.32M - Long-term debt
€51.07M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€5.99M - Total non-current liabilities
€364.74M - Total liabilities
€570.05M - Common stock
€6.86K - Retained earnings
-€622.84M - Other equity
€0.00 - Total equity
€92.37M - Total liabilities and shareholders' equity
€662.43M
Company information
- Market capitalization
€0.00 - Employees
302 - Enterprise Value
-€73.84M
Company ratios
- Gross margin
-
100.0% Much better than peer group: -132.2% - EBITDA margin
-
-61.5% Much better than peer group: -230.6% - EBIT margin
-
-62.9% Much better than peer group: -240.1% - EBT margin
-
-63.8% Much better than peer group: -238.4% - Net margin
-
-64.5% Much better than peer group: -239.4% - ROE
-
-115.6% Much worse than peer group: 4.5% - ROA
-
-16.1% Worse than peer group: 2.7% - Asset turnover
-
25.0% Much worse than peer group: 103.7% - FCF margin
-
4.4% Much better than peer group: -203.3% - FCF yield
0.0% - Efficiency ratio
161.5% - Net sales per employee
-
€547.90K - Net income per employee
-
-€353.54K